Clinical trials for glioma patients at the Finnish BNCT facility

Iiro Auterinen; Leena Kankaanranta; Sauli Savolainen; Tiina Seppälä; Markus Färkkilä; Merja Kallio; Martti Kulvik; Juha Laakso; Eija Järviluoma; Merja Rasilainen; Inkeri Ruokonen; Jyrki Vähätalo; Johanna Karila; Mika Kortesniemi; Petri Kotiluoto; Tom Serén; Mikko Tenhunen; Antti Brander; Anders Paetau; O. Salonen; Juha Jääskeläinen; Hanna Mäenpää; Heikki Joensuu

Clinical trials for glioma patients at the Finnish BNCT facility

Iiro Auterinen, Leena Kankaanranta, Sauli Savolainen, Tiina Seppälä, Markus Färkkilä, Merja Kallio, Martti Kulvik, Juha Laakso, Eija Järviluoma, Merja Rasilainen, Inkeri Ruokonen, Jyrki Vähätalo, Johanna Karila, Mika Kortesniemi, Petri Kotiluoto, Tom Serén, Mikko Tenhunen, Antti Brander, Anders Paetau, O. SalonenJuha Jääskeläinen, Hanna Mäenpää, Heikki Joensuu

Research output: Chapter in Book/Report/Conference proceeding › Conference abstract in proceedings › Scientific

Abstract

Boron neutron capture therapy (BNCT) is an experimental radiotherapy used in clinical trials in Europe, Japan and USA to treat malignant glioma and melanoma. In BNCT the highly lethal radiation (a, 7Li*) released in thermal neutron capture of boron-1 atoms is used. The dose is targeted to the tumour using a boron carrier substance that is selectively taken up by the cancerous tissue. Clinical trials using borono-phenylalanine fructose complex (BPA-F) for the highly malignant brain tumour glioblast ma started at FiR 1 BNCT facility at VTT in May 1999. The neutron beam as well as the treatment environment, equipment and methods are of world top quality [1,2,3,4]. Patients are currently recruited to two clinical research protocols. By December 200118 newly diag-nosed, operated, but otherwise previously untreated patients have been treated in the first protocol using 290 mg/kg - 400 mg/kg BPA-F. BPA-F escalation p to 500 mg/ kg is planned for. The two hour BPA-F infusion has proofed safe and well tolerated. No severe late radiation therapy effects have been found. The acute and sub-acute toxicity has been acceptable. Since February 2001 three patients with recurrent glioblastoma have been treated using 290 mg/kg BPA-F. The radiation dose for these patients has been lower as compared to the first protocol due to the prior conventional RT given a minimum of six months before BNCT as part of conventional treatment for glioma. Also for these patients the BNCT treatment has been well tolerated and the adverse effects have been acceptable. First results suggest a prolonged survival. With the given BPA-F and RT doses stable diseases and partial responses to the treatment have been seen but the tumours tend to recur. The preliminary results support continuation of the BNCT research. Future plans involve fractionating BNCT irradiation and combining BNCT with stereotactically guided photon radiotherapy. [1] T. Seppälä et al., in these proceedings. [2] M. Kortesniemi et al., in these proceedings. [3] P. Ryynänen et al., in these proceedings. [4] J. Laakso, M. Kulvik, I. Ruokonen, J. Vähätalo, R. Zilliacus, M. Färkkilä, M. Kallio, Clin Chem., vol. 47 (2001) 10, p. 1796

Original language	English
Title of host publication	Proceedings of the XXXVI Annual Conference of the Finnish Physical Society
Place of Publication	Joensuu
Publisher	University of Joensuu
ISBN (Print)	952-458-110-2
Publication status	Published - 2002
MoE publication type	Not Eligible
Event	XXXVI Annual Conference of the Finnish Physical Society - Joensuu, Finland Duration: 13 Mar 2002 → 16 Mar 2002 Conference number: 36

Publication series

Series	Selected papers. University of Joensuu, Department of Physics
Number	7
ISSN	1236-0376

Conference

Conference	XXXVI Annual Conference of the Finnish Physical Society
Country/Territory	Finland
City	Joensuu
Period	13/03/02 → 16/03/02

Cite this

Auterinen, I., Kankaanranta, L., Savolainen, S., Seppälä, T., Färkkilä, M., Kallio, M., Kulvik, M., Laakso, J., Järviluoma, E., Rasilainen, M., Ruokonen, I., Vähätalo, J., Karila, J., Kortesniemi, M., Kotiluoto, P., Serén, T., Tenhunen, M., Brander, A., Paetau, A., ... Joensuu, H. (2002). Clinical trials for glioma patients at the Finnish BNCT facility. In Proceedings of the XXXVI Annual Conference of the Finnish Physical Society Article 158 University of Joensuu.

@inbook{c4322f4b783549daba75a236abf13472,

title = "Clinical trials for glioma patients at the Finnish BNCT facility",

abstract = "Boron neutron capture therapy (BNCT) is an experimental radiotherapy used in clinical trials in Europe, Japan and USA to treat malignant glioma and melanoma. In BNCT the highly lethal radiation (a, 7Li*) released in thermal neutron capture of boron-1 atoms is used. The dose is targeted to the tumour using a boron carrier substance that is selectively taken up by the cancerous tissue. Clinical trials using borono-phenylalanine fructose complex (BPA-F) for the highly malignant brain tumour glioblast ma started at FiR 1 BNCT facility at VTT in May 1999. The neutron beam as well as the treatment environment, equipment and methods are of world top quality [1,2,3,4]. Patients are currently recruited to two clinical research protocols. By December 200118 newly diag-nosed, operated, but otherwise previously untreated patients have been treated in the first protocol using 290 mg/kg - 400 mg/kg BPA-F. BPA-F escalation p to 500 mg/ kg is planned for. The two hour BPA-F infusion has proofed safe and well tolerated. No severe late radiation therapy effects have been found. The acute and sub-acute toxicity has been acceptable. Since February 2001 three patients with recurrent glioblastoma have been treated using 290 mg/kg BPA-F. The radiation dose for these patients has been lower as compared to the first protocol due to the prior conventional RT given a minimum of six months before BNCT as part of conventional treatment for glioma. Also for these patients the BNCT treatment has been well tolerated and the adverse effects have been acceptable. First results suggest a prolonged survival. With the given BPA-F and RT doses stable diseases and partial responses to the treatment have been seen but the tumours tend to recur. The preliminary results support continuation of the BNCT research. Future plans involve fractionating BNCT irradiation and combining BNCT with stereotactically guided photon radiotherapy. [1] T. Sepp{\"a}l{\"a} et al., in these proceedings. [2] M. Kortesniemi et al., in these proceedings. [3] P. Ryyn{\"a}nen et al., in these proceedings. [4] J. Laakso, M. Kulvik, I. Ruokonen, J. V{\"a}h{\"a}talo, R. Zilliacus, M. F{\"a}rkkil{\"a}, M. Kallio, Clin Chem., vol. 47 (2001) 10, p. 1796",

author = "Iiro Auterinen and Leena Kankaanranta and Sauli Savolainen and Tiina Sepp{\"a}l{\"a} and Markus F{\"a}rkkil{\"a} and Merja Kallio and Martti Kulvik and Juha Laakso and Eija J{\"a}rviluoma and Merja Rasilainen and Inkeri Ruokonen and Jyrki V{\"a}h{\"a}talo and Johanna Karila and Mika Kortesniemi and Petri Kotiluoto and Tom Ser{\'e}n and Mikko Tenhunen and Antti Brander and Anders Paetau and O. Salonen and Juha J{\"a}{\"a}skel{\"a}inen and Hanna M{\"a}enp{\"a}{\"a} and Heikki Joensuu",

note = "Probably ext.abstract.; XXXVI Annual Conference of the Finnish Physical Society ; Conference date: 13-03-2002 Through 16-03-2002",

year = "2002",

language = "English",

isbn = "952-458-110-2",

series = "Selected papers. University of Joensuu, Department of Physics",

publisher = "University of Joensuu",

number = "7",

booktitle = "Proceedings of the XXXVI Annual Conference of the Finnish Physical Society",

address = "Finland",

}

Auterinen, I, Kankaanranta, L, Savolainen, S, Seppälä, T, Färkkilä, M, Kallio, M, Kulvik, M, Laakso, J, Järviluoma, E, Rasilainen, M, Ruokonen, I, Vähätalo, J, Karila, J, Kortesniemi, M, Kotiluoto, P, Serén, T, Tenhunen, M, Brander, A, Paetau, A, Salonen, O, Jääskeläinen, J, Mäenpää, H & Joensuu, H 2002, Clinical trials for glioma patients at the Finnish BNCT facility. in Proceedings of the XXXVI Annual Conference of the Finnish Physical Society., 158, University of Joensuu, Joensuu, Selected papers. University of Joensuu, Department of Physics, no. 7, XXXVI Annual Conference of the Finnish Physical Society, Joensuu, Finland, 13/03/02.

Clinical trials for glioma patients at the Finnish BNCT facility. / Auterinen, Iiro; Kankaanranta, Leena; Savolainen, Sauli et al.
Proceedings of the XXXVI Annual Conference of the Finnish Physical Society. Joensuu: University of Joensuu, 2002. 158 (Selected papers. University of Joensuu, Department of Physics; No. 7).

Research output: Chapter in Book/Report/Conference proceeding › Conference abstract in proceedings › Scientific

TY - CHAP

T1 - Clinical trials for glioma patients at the Finnish BNCT facility

AU - Auterinen, Iiro

AU - Kankaanranta, Leena

AU - Savolainen, Sauli

AU - Seppälä, Tiina

AU - Färkkilä, Markus

AU - Kallio, Merja

AU - Kulvik, Martti

AU - Laakso, Juha

AU - Järviluoma, Eija

AU - Rasilainen, Merja

AU - Ruokonen, Inkeri

AU - Vähätalo, Jyrki

AU - Karila, Johanna

AU - Kortesniemi, Mika

AU - Kotiluoto, Petri

AU - Serén, Tom

AU - Tenhunen, Mikko

AU - Brander, Antti

AU - Paetau, Anders

AU - Salonen, O.

AU - Jääskeläinen, Juha

AU - Mäenpää, Hanna

AU - Joensuu, Heikki

N1 - Conference code: 36

PY - 2002

Y1 - 2002

N2 - Boron neutron capture therapy (BNCT) is an experimental radiotherapy used in clinical trials in Europe, Japan and USA to treat malignant glioma and melanoma. In BNCT the highly lethal radiation (a, 7Li*) released in thermal neutron capture of boron-1 atoms is used. The dose is targeted to the tumour using a boron carrier substance that is selectively taken up by the cancerous tissue. Clinical trials using borono-phenylalanine fructose complex (BPA-F) for the highly malignant brain tumour glioblast ma started at FiR 1 BNCT facility at VTT in May 1999. The neutron beam as well as the treatment environment, equipment and methods are of world top quality [1,2,3,4]. Patients are currently recruited to two clinical research protocols. By December 200118 newly diag-nosed, operated, but otherwise previously untreated patients have been treated in the first protocol using 290 mg/kg - 400 mg/kg BPA-F. BPA-F escalation p to 500 mg/ kg is planned for. The two hour BPA-F infusion has proofed safe and well tolerated. No severe late radiation therapy effects have been found. The acute and sub-acute toxicity has been acceptable. Since February 2001 three patients with recurrent glioblastoma have been treated using 290 mg/kg BPA-F. The radiation dose for these patients has been lower as compared to the first protocol due to the prior conventional RT given a minimum of six months before BNCT as part of conventional treatment for glioma. Also for these patients the BNCT treatment has been well tolerated and the adverse effects have been acceptable. First results suggest a prolonged survival. With the given BPA-F and RT doses stable diseases and partial responses to the treatment have been seen but the tumours tend to recur. The preliminary results support continuation of the BNCT research. Future plans involve fractionating BNCT irradiation and combining BNCT with stereotactically guided photon radiotherapy. [1] T. Seppälä et al., in these proceedings. [2] M. Kortesniemi et al., in these proceedings. [3] P. Ryynänen et al., in these proceedings. [4] J. Laakso, M. Kulvik, I. Ruokonen, J. Vähätalo, R. Zilliacus, M. Färkkilä, M. Kallio, Clin Chem., vol. 47 (2001) 10, p. 1796

AB - Boron neutron capture therapy (BNCT) is an experimental radiotherapy used in clinical trials in Europe, Japan and USA to treat malignant glioma and melanoma. In BNCT the highly lethal radiation (a, 7Li*) released in thermal neutron capture of boron-1 atoms is used. The dose is targeted to the tumour using a boron carrier substance that is selectively taken up by the cancerous tissue. Clinical trials using borono-phenylalanine fructose complex (BPA-F) for the highly malignant brain tumour glioblast ma started at FiR 1 BNCT facility at VTT in May 1999. The neutron beam as well as the treatment environment, equipment and methods are of world top quality [1,2,3,4]. Patients are currently recruited to two clinical research protocols. By December 200118 newly diag-nosed, operated, but otherwise previously untreated patients have been treated in the first protocol using 290 mg/kg - 400 mg/kg BPA-F. BPA-F escalation p to 500 mg/ kg is planned for. The two hour BPA-F infusion has proofed safe and well tolerated. No severe late radiation therapy effects have been found. The acute and sub-acute toxicity has been acceptable. Since February 2001 three patients with recurrent glioblastoma have been treated using 290 mg/kg BPA-F. The radiation dose for these patients has been lower as compared to the first protocol due to the prior conventional RT given a minimum of six months before BNCT as part of conventional treatment for glioma. Also for these patients the BNCT treatment has been well tolerated and the adverse effects have been acceptable. First results suggest a prolonged survival. With the given BPA-F and RT doses stable diseases and partial responses to the treatment have been seen but the tumours tend to recur. The preliminary results support continuation of the BNCT research. Future plans involve fractionating BNCT irradiation and combining BNCT with stereotactically guided photon radiotherapy. [1] T. Seppälä et al., in these proceedings. [2] M. Kortesniemi et al., in these proceedings. [3] P. Ryynänen et al., in these proceedings. [4] J. Laakso, M. Kulvik, I. Ruokonen, J. Vähätalo, R. Zilliacus, M. Färkkilä, M. Kallio, Clin Chem., vol. 47 (2001) 10, p. 1796

M3 - Conference abstract in proceedings

SN - 952-458-110-2

T3 - Selected papers. University of Joensuu, Department of Physics

BT - Proceedings of the XXXVI Annual Conference of the Finnish Physical Society

PB - University of Joensuu

CY - Joensuu

T2 - XXXVI Annual Conference of the Finnish Physical Society

Y2 - 13 March 2002 through 16 March 2002

ER -

Clinical trials for glioma patients at the Finnish BNCT facility

Abstract

Publication series

Conference

Fingerprint

Cite this